RBC Capital analyst Luca Issi lowered the firm’s price target on Dyne Therapeutics (DYN) to $23 from $25 and keeps an Outperform rating on the shares. The firm updated its model following the Q2 earnings report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics: Promising Clinical Developments and Strategic Positioning Drive Buy Rating
- Dyne Therapeutics Advances in Neuromuscular Therapies
- Dyne Therapeutics reports Q2 EPS (97c), consensus (93c)
- Dyne Therapeutics expects cash to fund operations into Q3 of 2027
- Dyne Therapeutics CEO buys $911K in common stock